Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now



September 21-23, 2010 • New York City

Save the date in your Microsoft Outlook Calendar


Interested in presenting at a Windhover conference?
Submit your idea here

WHY ATTEND PSA?

Simple. Meet the most important people in the business.

The BIGGEST Names are Sending their Leadership Teams to PSA. And the hotel WILL sell out soon.

Unprecedented networking.


Attend the ONLY strategic-level conference that delivers 100% case studies by the most important people in the business.

Benchmark your corporate strategies against the best and the brightest.

Featuring special guest speaker Mark McClellan on Pharma R&D: The New Customers Revaluing Its Output and Determining Its Direction
 Mark McClellan, the most creative administrator the FDA and CMS have ever had (indeed, the only person to ever serve at the top of both agencies), and who is now the force behind some of the most innovative changes in payer and customer buying behavior, addresses the future of pharma R & D models.
Mark McClellan Mark McClellan, MD
Former Administrator
Medicare Medicaid
Director, Engelberg Center for Health Care Reform
The Brookings Institution

Featuring the workshop More Ways to Win: The Outlook for Pharma in 2020
In this workshop, Robin Arnold, vice president of IMS Health's Product and Portfolio Strategy practice, will reveal insights from the company's recent global study of pharmaceutical market growth opportunities over the next decade. The study uncovers new insights about the most promising areas for long-term investment and de-prioritization, the potential of R&D pipelines, emerging therapy approaches and the impact of early patient intervention on growth, along with raising important questions about how pharmaceutical companies can better prepare for a more promising, but uncertain future. Robin Arnold Robin Arnold
Vice President
IMS Health

Additional featured speakers include:
Roger Longman
former Managing Partner
Windhover Information

Shaun Grady
Vice President, Strategic Partnering and Corporate Business Development
AstraZeneca Plc

David Donabedian, PhD, M.B.A.
VP Strategic Alliances, US Centre of Excellence for External Drug Discovery
GlaxoSmithKline

Gino Santini
Senior Vice President, Corporate Strategy
Eli Lilly and Company


Robert S. Epstein, MD, MS
Chief Medical Officer & President, Medco Research Institute
Medco Health Solutions, Inc.

Andrew Curtis
Head of Biosimilars and Orphan Drugs
Pfizer
Rich Tillyer
Senior Vice President, Worldwide Preclinical Development
Merck & Company

Michael Kamarck
President, Merck BioVentures
Senior Vice President Vaccines and Biologics Manufacturing
Merck & Company

James Sabry, MD, PhD
Vice President of Partnering
Genentech

George Golumbeski
SVP Business Development
Celgene

Dr. Stefan J. Oschmann
President, Emerging Markets
Merck & Company

Jean Michel Halfon
President and General Manager, Emerging Markets Business Unit
Pfizer

After the Patent Cliff: Shared Risk For Shared Reward

The biopharma landscape of 2010 is dramatically different than one year ago but no less complex. Almost universally, the au courant phrase is shared risk for shared reward. The shift in mindset driving this thinking is subtle; to succeed, it implies if not an explicit partnership then an implicit compromise between parties such as small biotech and big pharma, and drug developer and payor. The ramifications of this shift, which will encompass every player in the biopharma drug development ecosystem, are already influencing dealmaking decisions.

At this year’s Pharmaceutical Strategic Alliances conference, we’ll gather some of the industry’s newest faces to enlighten us all on the concept of risk-sharing in its various facets:

Option-based deals, while not new, came into their own in 2009 and continue to be a force in 2010. VCs may increasingly look to risk-sharing alliances or options-to-acquire as a means to hedge the development costs of their portfolio companies, building their start-ups for this eventuality. Pharmas, eager to shed unnecessary infrastructure, will continue to push for alliances, or partial ownership structures where appropriate. They must also determine the best way to work with payors, especially in the US market.

Almost certainly the risk-sharing deals of tomorrow will be as varied as their developers, with an emphasis on bespoke arrangements that mirror the tailoring of medicines to individual patients. Join us this September at Pharmaceutical Strategic Alliances conference, where we’ll gather some of the industry’s newest faces to examine the concept of risk-sharing in its various facets.

Why attend PSA?

  • Meet your potential partner and find out how to approach them
  • Understand externalization models and see if your approach fits your potential partner's positioning
  • Benchmark your dealmaking strategy against what your competitors are doing and why
  • Learn the deal values and deal specifics that let you calibrate deal-making metrics

Maximize your strategic alliance opportunities by hearing CEOs, Senior R&D and Senior Business Development executives who share lessons learned, practical advice and strategies on how to build your R&D pipeline--both internally and externally.

And this September, PSA offers you an unbeatable line-up of Big Pharma and biotech speakers to forecast trends and analyze changes in alliances and M&A. You’ll hear from, and be able to quiz, top industry executives and dealmakers.

PSA gathers top thinkers to grapple with the fundamental challenges facing biotech and pharma – equipping dealmakers like you with the insights, information and practical advice you'll need to strike successful deals. This program will sell out so register early. Space is limited, so register today!

Top dealmakers around the industry are talking about Pharmaceutical Strategic Alliances...

“PSA’s 20th anniversary demonstrates the ongoing value of our powerful content, deep insight and expert analysis, year after year.”
Roger Longman

“Great meeting. Venue and meeting size were conducive to great access and networking.”
Mohan Chukkapalli, Director, Business Development, Novo Nordisk Inc.

“A great forum to interact with leading people from across the pharma industry.”
Troy Harmon, VP, Business Development, Eurand

“Topics and speakers excellent as usual. I travel to NYC each year to keep up to date on Pharma trends and paradigm shifts.”
Audrey Erbes, Ph.D., Principal, Erbes & Associates

See you at the Millennium Broadway, New York City, this Sept. 21-23!

Cancellation Policy: The last day to cancel your registration for a refund, minus a $300 processing fee, is August 21. After that, you may send another delegate from your company.

Sponsors

Global Sponsors
EAPD IMS

McKinsey and Co.
Gold Industry Sponsors

AD Little









Silver Industry Sponsors

Bayer Health Care

Eurand

Gerson Lehman Group

Workshop Sponsors

Deloitte

IMS


Major Supporting Publications

IN VIVO

Start-Up











Media Partners

Angel News





NYCEDC

Regional Supporting Organization

BIOTECanada


Networking Break Sponsor

Ontario, CA

The IN VIVO Blog

Pharmaceutical Strategic Alliances
September 21-23, 2010 · New York, NY

PharmAsia Summit
October 25-26, 2010 · San Francisco, CA

IN3 Summit
October 27-29, 2010 · San Francisco, CA

Interested in presenting at a Windhover conference?
Submit your idea here


Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)

Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)

Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)

FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - Webinars - About Us - Contact Us - Help - The IN VIVO Blog - RSS Feeds - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence